Allergy Therapeutics agrees refinancing package
Allergy Therapeutics PLC, which is headquartered in Worthing, West Sussex and employs around 500 people, develops inoculations against common allergies
Company
Allergy Therapeutics PLC
LON:AGY
Allergy Therapeutics PLC is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The company sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
298 stories · page 5 of 15
Allergy Therapeutics says patient screening for exploratory field study of short-course grass allergy immunotherapy has begun
"This exploratory grass trial will drive study design innovation in the allergy field and is an important intermediate step for the optimisation of our upcoming pivotal phase III grass field trial, which will maximise the chances of success
Allergy Therapeutics sees growth across Europe as new trials approach
Bee sting treatment Venomil continued to grow very strongly, said Allergy
Allergy Therapeutics broadens its collaboration with vaccine pair in a deal that takes it into oncology
The company is currently developing a peanut allergy inoculation based on technology pioneered by Saiba and DeepVax
Allergy Therapeutics earnings to exceed expectations after a strong year
Net revenues for the 12 months ended June 30 were £78.2mln, up 6% year-on-year
Allergy Therapeutics allowed to hit the reset button on birch pollen phase III trial
“We remain committed to Birch MATA MPL, especially considering the results of the independent secondary endpoint data and the supportive safety profile observed in the B301 study and two successful phase II trials showing significant primar
Allergy Therapeutics gets big forecast upgrade from finncap after trading update
The broker now expects profits to around £5m higher than its previous forecasts at £2.9m.
Allergy Therapeutics says 2020 net profit will be well ahead of expectations
The update was provided in a brief trading statement
Allergy Therapeutics welcomes academic paper's endorsement of adjuvant technology
“We have developed biodegradable adjuvants that make allergy treatment more efficient than ever - a key technology in our pioneering approach to the development of innovative treatments for allergy patients"
Allergy Therapeutics hails "steady" first half performance; finnCap ups forecasts
The company ended the half-way period in a strong cash position with just under £40mln in the bank
Allergy Therapeutics: Journal article flags up potential of peanut vaccine
The data from the firm’s early-stage study was carried in The Journal of Allergy and Clinical Immunology
Allergy Therapeutics sees sales grow in all countries
Revenues rose by 9% in the six months to December to £50.5mln
Allergy Therapeutics opts to split phase III grass allergy study over two pollen seasons
It has done so after consulting experts and taking on board feedback from its phase III Birch MATA MPL trial
Allergy Therapeutics enjoys a strong and profitable year
The vaccines specialist weighed in with an 8% boost to revenues on a constant currencies basis to £73.7mln, giving ‘pre-R&D’ operating earnings of £11.3mln, up 22%
Archive
FTSE 100 closes almost flat as US stocks rally on Trump trade war optimism
At the close, the UK blue chip index was only 1.44 points lower at 7.282.99, just off the late peak of 7,292.00 and well above the session low
Archive
Proactive news snapshot: Hurricane Energy PLC , Allergy Therapeutics, Polarean Imaging, Benchmark Holdings …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Attis surges after increasing production levels
A look at the day's major movers, including GCM, Alexander Mining, Jubilee Metals, McBride, Sosandar and Tekcapital
Allergy Therapeutics continues to trade ahead of expectations as it makes market share gains
In a comprehensive update on trading, the group said net revenue for the year is expected to be £73.7mln, up 8% on last year, while cash at the end of June was £27.4mln
Investments and investor services
FTSE 100 closes lower again as European shares slide as mood sours
Footsie closed on Thursday nearly 21 points lower at 7,509.
Archive
Proactive news snapshot: Richland Resources, Kromek, Powerhouse Energy, Allergy Therapeutics …
A glance at some of the day's highlights from the Proactive Investors newswire